- Home
- UAN vs AVXL Comparison
UAN vs AVXL Comparison
Compare UAN & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAN
- AVXL
- Stock Information
- Founded
- UAN 2007
- AVXL 2004
- Country
- UAN United States
- AVXL United States
- Employees
- UAN N/A
- AVXL N/A
- Industry
- UAN Agricultural Chemicals
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UAN Industrials
- AVXL Health Care
- Exchange
- UAN Nasdaq
- AVXL Nasdaq
- Market Cap
- UAN 943.7M
- AVXL 956.7M
- IPO Year
- UAN 2011
- AVXL N/A
- Fundamental
- Price
- UAN $91.59
- AVXL $9.95
- Analyst Decision
- UAN
- AVXL Strong Buy
- Analyst Count
- UAN 0
- AVXL 2
- Target Price
- UAN N/A
- AVXL $44.00
- AVG Volume (30 Days)
- UAN 30.0K
- AVXL 1.2M
- Earning Date
- UAN 07-30-2025
- AVXL 08-12-2025
- Dividend Yield
- UAN 7.41%
- AVXL N/A
- EPS Growth
- UAN 77.68
- AVXL N/A
- EPS
- UAN 8.32
- AVXL N/A
- Revenue
- UAN $576,184,000.00
- AVXL N/A
- Revenue This Year
- UAN N/A
- AVXL N/A
- Revenue Next Year
- UAN N/A
- AVXL N/A
- P/E Ratio
- UAN $10.97
- AVXL N/A
- Revenue Growth
- UAN 8.15
- AVXL N/A
- 52 Week Low
- UAN $62.94
- AVXL $4.93
- 52 Week High
- UAN $98.99
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- UAN 51.69
- AVXL 39.87
- Support Level
- UAN $95.00
- AVXL $9.90
- Resistance Level
- UAN $98.99
- AVXL $11.70
- Average True Range (ATR)
- UAN 2.74
- AVXL 0.70
- MACD
- UAN -0.63
- AVXL -0.23
- Stochastic Oscillator
- UAN 31.10
- AVXL 1.62
About UAN CVR Partners LP Common Units representing Limited Partner Interests
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.